ARC-18 Improved Motor Performance Through Inhibiting ACLY-Mediated Smad2/3 Acetylation in a Model of Duchenne Muscular Dystrophy.

J Cachexia Sarcopenia Muscle · 2025 · PMC12501411 · PMID 41054284

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

Both ARC‐18 and DFZ treatments enhanced functional outcomes, and while high‐dose ARC‐18 treated mice showed a trend toward better performance in hanging endurance compared to DFZ treated mice (hanging time +7.9%), this difference did not reach statistical significance (Figure 1B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.